Bowel Perforation from Bevacizumab for the Treatment of Metastatic Colon Cancer: Incidence, Etiology, and Management

John H. Heinzerling; Sergio Huerta

doi:10.1016/j.cursur.2006.06.002

Bowel Perforation from Bevacizumab for the Treatment of Metastatic Colon Cancer: Incidence, Etiology, and Management

John H. Heinzerling, Sergio Huerta

Research output: Contribution to journal › Article › peer-review

83 Scopus citations

Abstract

Avastin (Bevacizumab) is a recently developed monoclonal antibody against vascular endothelial growth factor (VEGF) receptor that increases survival in patients with metastatic colorectal cancer. Bowel perforation is a known risk factor of unknown etiology associated with the use of Avastin. In this report, the incidence, risk factors, typical presentation, and management of patients with this complication is described.

Original language	English (US)
Pages (from-to)	334-337
Number of pages	4
Journal	Current surgery
Volume	63
Issue number	5
DOIs	https://doi.org/10.1016/j.cursur.2006.06.002
State	Published - Sep 2006

Keywords

Avastin
Bevacizumab
acute abdomen
bowel perforation
chemotherapy
colon cancer
immunotherapy

ASJC Scopus subject areas

Surgery

Access to Document

10.1016/j.cursur.2006.06.002

Cite this

@article{ef99ab9d42ca430db1a155fa4d5feb4d,

title = "Bowel Perforation from Bevacizumab for the Treatment of Metastatic Colon Cancer: Incidence, Etiology, and Management",

abstract = "Avastin (Bevacizumab) is a recently developed monoclonal antibody against vascular endothelial growth factor (VEGF) receptor that increases survival in patients with metastatic colorectal cancer. Bowel perforation is a known risk factor of unknown etiology associated with the use of Avastin. In this report, the incidence, risk factors, typical presentation, and management of patients with this complication is described.",

keywords = "Avastin, Bevacizumab, acute abdomen, bowel perforation, chemotherapy, colon cancer, immunotherapy",

author = "Heinzerling, {John H.} and Sergio Huerta",

year = "2006",

month = sep,

doi = "10.1016/j.cursur.2006.06.002",

language = "English (US)",

volume = "63",

pages = "334--337",

journal = "Current surgery",

issn = "0149-7944",

publisher = "Elsevier Inc.",

number = "5",

}

TY - JOUR

T1 - Bowel Perforation from Bevacizumab for the Treatment of Metastatic Colon Cancer

T2 - Incidence, Etiology, and Management

AU - Heinzerling, John H.

AU - Huerta, Sergio

PY - 2006/9

Y1 - 2006/9

N2 - Avastin (Bevacizumab) is a recently developed monoclonal antibody against vascular endothelial growth factor (VEGF) receptor that increases survival in patients with metastatic colorectal cancer. Bowel perforation is a known risk factor of unknown etiology associated with the use of Avastin. In this report, the incidence, risk factors, typical presentation, and management of patients with this complication is described.

AB - Avastin (Bevacizumab) is a recently developed monoclonal antibody against vascular endothelial growth factor (VEGF) receptor that increases survival in patients with metastatic colorectal cancer. Bowel perforation is a known risk factor of unknown etiology associated with the use of Avastin. In this report, the incidence, risk factors, typical presentation, and management of patients with this complication is described.

KW - Avastin

KW - Bevacizumab

KW - acute abdomen

KW - bowel perforation

KW - chemotherapy

KW - colon cancer

KW - immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=33748426175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748426175&partnerID=8YFLogxK

U2 - 10.1016/j.cursur.2006.06.002

DO - 10.1016/j.cursur.2006.06.002

M3 - Article

C2 - 16971205

AN - SCOPUS:33748426175

SN - 0149-7944

VL - 63

SP - 334

EP - 337

JO - Current surgery

JF - Current surgery

IS - 5

ER -

Bowel Perforation from Bevacizumab for the Treatment of Metastatic Colon Cancer: Incidence, Etiology, and Management

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this